echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > The first antibody drug to target BCMA, Blenrep, was approved by the FDA for accelerated treatment of recurrent or recurrent multiple myeloma.

    The first antibody drug to target BCMA, Blenrep, was approved by the FDA for accelerated treatment of recurrent or recurrent multiple myeloma.

    • Last Update: 2020-08-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    GlaxoSmithKline announced that the FDA has accelerated approval of Belantamab mafodotin-blmf for the treatment of adult patients with recurrent or recurrent multiple myeloma who have received at least four previous treatments, including anti-CD38 monoclonal antibodies, protease inhibitors, and immunomodants.
    photo Source: Blenrep is an antibody-drug concatile (ADC) that targets B-cell mature antigens (B Cell Maturation Antigens), a drug that connects anti-BCMA monoantimmune to the cytotoxic drug monomethyl auristatin-F via a connecting subn.
    anti-BCMA monoantigens are targeted to bind to BCMA on the surface of multiple myeloma cells, which are then internalized by tumor cells to release non-permeable cytotoxic drugs to play an anti-tumor role.
    GSK noted that FDA approval makes Blenrep the world's first antibody-drug concoant to target BCMA.
    the FDA Advisory Group approved the drug by a vote of 12 to 0.
    but the eye toxicity of Blenrep was observed in key DREAM-2 trials.
    corneal lesions were the most common adverse events in the study, with a total rate of 71%, while 44% of patients experienced at least one serious corneal lesion at a dose of 2.5 mg/kg.
    Recently, the European Medicines Agency's Human Medicines Committee recommended that Blunrep be granted conditional market approval to treat patients with recurrent and recurrent multiple myeloma who are ineffective in the treatment of immunomodants, protease inhibitors and CD-38 monoclonal antibodies.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.